Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <em>Mycobacterium tuberculosis</em>: A case report

Kobayashi,Kunihiko; Kaira,Kyoichi; Iemura,Hidetoshi; Shinomiya,Shun; Hashimoto,Kosuke; Miura,Yu; Shiono,Ayako; Nishihara,Fuyumi; Kagamu,Hiroshi

doi:10.3892/mco.2021.2390

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report

Authors:
- Kunihiko Kobayashi
- Kyoichi Kaira
- Hidetoshi Iemura
- Shun Shinomiya
- Kosuke Hashimoto
- Yu Miura
- Ayako Shiono
- Fuyumi Nishihara
- Hiroshi Kagamu
View Affiliations

Affiliations: Department of Respiratory Medicine, Saitama International Medical Center, Saitama Medical University, Saitama 350‑1298, Japan
Published online on: September 7, 2021 https://doi.org/10.3892/mco.2021.2390
Article Number: 227
Copyright: © Kobayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study selected two patients with lung cancer and epidermal growth factor receptor (EGFR) mutations who were treated with a programmed cell death protein 1 (PD‑1) antibody and an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis. In the first case, a 67‑year‑old female was diagnosed with lung adenocarcinoma with an EGFR mutation (exon 19 deletion) and Stage IVB disease. Initial treatment with an EGFR mutation‑targeted tyrosine kinase inhibitor (TKI), erlotinib, demonstrated a partial response. After disease progression this was followed by carboplatin and pemetrexed with bevacizumab, and re‑challenged by erlotinib plus bevacizumab; however, the tumor eventually progressed. Subsequently, the patient was treated with immunomodulatory arabinomannan for 3 months. Immediately after, she was treated with nivolumab and showed a partial response. In the second case, a 57‑year‑old male with a history of smoking was diagnosed with stage IVB pulmonary adenocarcinoma with an EGFR mutation (exon 19 deletion). He was treated with afatinib, followed by osimertinib when a T790M mutation was identified later. After disease progressed with TKIs, cisplatin plus pemetrexed and re‑challenge with erlotinib plus bevacizumab were administered subsequently. Nivolumab was administered for recurrent disease. Although he experienced tumor remission, regrowth of the tumors was observed. Under continuing nivolumab, he was treated by palliative irradiation treatments to the right pelvic bone metastasis and left adrenal metastasis with immunomodulatory arabinomannan. A chest computed tomography scan showed a reduction in the sizes of the primary site and pulmonary metastases, with a decreasing trend of carcinoma embryonic antigen. Overall, these cases may indicate that the immune adjuvant actions of immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis improves the effect of PD‑1 antibody treatments.

View Figures

View References

1	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.PubMed/NCBI View Article : Google Scholar
2	Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018.PubMed/NCBI View Article : Google Scholar
3	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
4	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive Non-Small-Cell lung cancer. N Engl J Med. 375:1823–1833. 2016.PubMed/NCBI View Article : Google Scholar
5	Busch W: Einfluβ von Erysipel. Berliner Klin Wschr. 3:245–246. 1866.(In German).
6	Maruyama C: On the treatment of malignant tumor with an extract from tubercle bacilli. Jpn J Dermatol. 76:399–404. 1966.(In Japanese).
7	Tsung K and Norton JA: Lessons from Coley's Toxin. Surg Oncol. 15:25–28. 2006.PubMed/NCBI View Article : Google Scholar
8	Kobatake H, Suekane T, Murakami Y, Niwa S, Okahira A and Kushida H: Studies on hot water extract of Mycobacterium tuberculosis. I. Structural analyses of polysaccharides (author's transl). Yakugaku Zasshi. 101:713–722. 1981.PubMed/NCBI View Article : Google Scholar : (In Japanese).
9	Oka H, Shiraishi Y, Sasaki H, Yoshinaga K, Emori Y and Takei M: Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12. Biol Pharm Bull. 26:1336–1341. 2003.PubMed/NCBI View Article : Google Scholar
10	Oka H, Emori Y, Sasaki H, Shiraishi Y, Yoshinaga K and Kurimoto T: Anti-tumor mechanism of Z-100, an immunomodulatory Arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, on pulmonary metastases of B16F10 melanoma: Restoration of helper T cell responses via suppression of glucocorticoid-genesis. Microbiol Immunol. 46:343–351. 2002.PubMed/NCBI View Article : Google Scholar
11	Oka H, Sasaki H, Shiraishi Y, Emori Y, Yoshinaga K and Takei M: Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1 T cell responses. Biol Pharm Bull. 27:82–88. 2004.PubMed/NCBI View Article : Google Scholar
12	Mitsuishi T, Kabashima K, Tanizaki H, Ohsawa I, Oda F, Yamada Y, Halifu Y, Kawana S, Kato T and Iida K: Specific substance of Maruyama (SSM) suppresses immune responses in atopic dermatitis-like skin lesions in DS-Nh mice by modulating dendritic cell functions. J Dermatol Sci. 63:184–190. 2011.PubMed/NCBI View Article : Google Scholar
13	Kobayashi K, Kaira K and Kagamu H: Recovery of the sensitivity to Anti-PD-1 antibody by celecoxib in lung cancer. Anticancer Res. 40:5309–5311. 2020.PubMed/NCBI View Article : Google Scholar
14	Murphy K and Weaver C: Chapters: 3-5. In: Janeway's Immunobiology. 9th edition. W.W. Norton & Company, Inc., New York, 2017.
15	Shah RR, Hassett KJ and Brito LA: Overview of vaccine adjuvants: Introduction, history, and current status. Methods Mol Biol. 1494:1–13. 2017.PubMed/NCBI View Article : Google Scholar
16	Reed SG, Orr MT and Fox CB: Key roles of adjuvants in modern vaccines. Nat Med. 19:1597–608. 2013.PubMed/NCBI View Article : Google Scholar
17	Hsu PC, Jablons DM, Yang CT and You L: Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci. 20(E3821)2019.PubMed/NCBI View Article : Google Scholar
18	Teng MW, Ngiow SF, Ribas A and Smyth MJ: Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75:2139–2145. 2015.PubMed/NCBI View Article : Google Scholar
19	Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203:1259–1271. 2006.PubMed/NCBI View Article : Google Scholar
20	Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851. 2018.PubMed/NCBI View Article : Google Scholar
21	Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K and Noda K: Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: A JGOG study. Ann Oncol. 25:1011–1017. 2014.PubMed/NCBI View Article : Google Scholar